A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Gemcabene (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Acronyms INDIGO-1
- Sponsors Gemphire Therapeutics
- 24 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 09 May 2017 According to a Gemphire Therapeutics media release, the company expects top-line data in early 2018.
- 15 Mar 2017 According to a Gemphire Therapeutics media release, first patient dosed in February 2017 with over 30 sites in the US and Canada.